Rain Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Rhea-AI Summary
Rain Therapeutics Inc. will be represented by CEO Avanish Vellanki at the Goldman Sachs 42nd Annual Global Healthcare Conference from June 8-11, 2021. He will present a corporate overview and engage in one-on-one investor meetings on June 10 at 5:30 p.m. ET. The presentation will be accessible via a webcast link and on the company's website. A replay will be available for 30 days following the event. Rain focuses on precision oncology, with its lead product RAIN-32 targeting MDM2 in various cancers.
Positive
- None.
Negative
- None.
News Market Reaction – RAIN
On the day this news was published, RAIN gained 1.50%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEWARK, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present a corporate overview and participate in one-on-one investor meetings at the Goldman Sachs 42nd Annual Global Healthcare Conference taking place virtually from June 8-11, 2021.
Presentation details can be found below:
Date: Thursday, June 10, 2021
Time: 5:30 p.m. ET
Location: Webcast Link – or at the company’s website (click here)
A replay of the presentation will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. For more information, visit www.rainthera.com.
Media Contact:
Grace Fotiades
LifeSci Communications
+1.646.876.5026
gfotiades@lifescicomms.com
FAQ
When is Rain Therapeutics presenting at the Goldman Sachs conference?
Who is presenting for Rain Therapeutics at the conference?
How can I watch the Rain Therapeutics presentation?
What is the focus of Rain Therapeutics?
What is RAIN-32?
